专利检索 ipc:"C07F9/6533" 第 1 页

1.

发明授权
Synthesis of Fmoc-protected morpholino monomers and their use in the synthesis of morpholino oligomer 有权

公开(公告)号：US12012427B2

公开(公告)日：2024-06-18

申请号：US17085201

申请日：2020-10-30

申请人： INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE

发明人： Surajit Sinha , Jayanta Kundu , Ujjwal Ghosh

IPC分类号： C08G73/06 , C07F9/6533 , C07F9/6558 , C07F9/6561

CPC分类号： C07F9/65616 , C07F9/6533 , C07F9/65583 , C08G73/06

摘要： Present invention relates to stable Fmoc protected Morpholino monomers and corresponding oligonucleotides (PMO) and efficient synthesis of the same involving chlorophosphoramidate and H-Phosphonate chemistry. Successful syntheses of the oligonucleotide with higher yield and lesser time have been accomplished employing solid phase synthesis and easy deprotection of Fmoc group with Piperidine.

2.

发明公开
QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION 审中-公开

公开(公告)号：US20240018174A1

公开(公告)日：2024-01-18

申请号：US18232909

申请日：2023-08-11

申请人： Ventana Medical Systems, Inc.

发明人： Christopher Bieniarz , Julia Ashworth-Sharpe , Brian D. Kelly , Nathan Polaske

IPC分类号： C07F9/6561 , C07F9/6518 , C07F9/6558 , C07F9/12 , C07D209/14 , C07H15/203 , C07H15/26 , C07F9/58 , C07F9/6503 , C12Q1/42 , C07H15/207 , G01N33/58 , C07D403/06 , C07F9/6533 , C07H17/02 , C07F9/06

CPC分类号： C07F9/6561 , C07F9/6518 , C07F9/65583 , C07F9/12 , C07D209/14 , C07H15/203 , C07H15/26 , C07F9/58 , C07F9/65031 , C12Q1/42 , C07H15/207 , G01N33/581 , C07D403/06 , C07F9/65335 , C07H17/02 , C07F9/06

摘要： Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.

3.

发明公开
COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER 审中-公开

公开(公告)号：US20230399304A1

公开(公告)日：2023-12-14

申请号：US18033269

申请日：2021-10-22

申请人： Dana-Farber Cancer Institute, Inc.

发明人： Nathanael S. Gray , Edward Chouchani , Tinghu Zhang , Narek Darabedian , Wenzhi JI , Jianwei Che

IPC分类号： C07D265/36 , C07D413/04 , C07D413/12 , C07D413/06 , C07F9/6533 , C07D217/24 , C07D401/12 , C07D498/04

CPC分类号： C07D265/36 , C07D413/04 , C07D413/12 , C07D413/06 , C07F9/65335 , C07D217/24 , C07D401/12 , C07D498/04

摘要： The present disclosure relates to compounds that are capable of inhibiting creatine kinase. The present disclosure also relates to methods of treating cancer, such as hematological malignancies.

4.

发明授权
Quinone methide analog signal amplification 有权

公开(公告)号：US11365210B2

公开(公告)日：2022-06-21

申请号：US16183570

申请日：2018-11-07

申请人： Ventana Medical Systems, Inc.

发明人： Christopher Bieniarz , Julia Ashworth-Sharpe , Brian D. Kelly , Nathan Polaske

IPC分类号： G01N33/58 , C07F9/6561 , C07F9/6518 , C07F9/6558 , C07F9/12 , C07D209/14 , C07H15/203 , C07H15/26 , C07F9/58 , C07F9/6503 , C12Q1/42 , C07D403/06 , C07F9/6533 , C07H17/02 , C07F9/06

摘要： Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.

5.

发明申请
ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE 有权

公开(公告)号：US20220170024A1

公开(公告)日：2022-06-02

申请号：US17552271

申请日：2021-12-15

申请人： Sarepta Therapeutics, Inc. , Murdoch University

发明人： Stephen Donald WILTON , Sue FLETCHER , Gunnar James HANSON , Richard Keith BESTWICK

IPC分类号： C12N15/113 , C07F9/6533

摘要： The present disclosure relates to antisense oligomers and related compositions and methods for inducing exon inclusion as a treatment for glycogen storage disease type II (GSD-II) (also known as Pompe disease, glycogenosis II, acid maltase deficiency (AMD), acid alpha-glucosidase deficiency, and lysosomal alpha-glucosidase deficiency), and more specifically relates to inducing inclusion of exon 2 and thereby restoring levels of enzymatically active acid alpha-glucosidase (GAA) protein encoded by the GAA gene.

6.

再颁专利
RNA interference compositions and methods for malignant tumors 有权

公开(公告)号：USRE48887E1

公开(公告)日：2022-01-11

申请号：US16576102

申请日：2019-09-19

申请人： Nitto Denko Corporation

发明人： Yoshiro Niitsu , Kenjirou Minomi , Bharat Majeti , Li Wang , Jihua Liu , Roger Adami , Wenbin Ying

IPC分类号： C07H21/04 , C12N15/113 , C07F9/6533 , C12Q1/02 , G01N33/58 , A61B5/00 , A61K49/00 , C07D311/30 , A61K31/713

摘要： This invention provides compositions for use in distributing active agents for treating a malignant tumor in a subject. The compositions contain RNAi molecules targeted to a human GST-π, along with RNAi molecules targeted to a human p21, and a pharmaceutically acceptable carrier. The carrier can include nanoparticles composed of an ionizable lipid, a structural lipid, one or more stabilizer lipids, and a lipid for reducing immunogenicity of the nanoparticles. This invention further provides methods for preventing or treating a malignant tumor by administering a therapeutically effective amount of an RNAi composition.

7.

发明授权
Morpholino oligonucleotide manufacturing method 有权

公开(公告)号：US11028386B2

公开(公告)日：2021-06-08

申请号：US16582392

申请日：2019-09-25

申请人： AJINOMOTO CO., INC.

发明人： Daisuke Takahashi , Takayoshi Torii

IPC分类号： C07F9/6558 , C07F9/6533 , C12N15/11 , C12N15/09 , C12N15/113 , A61K31/7052

摘要： Morpholino oligonucleotides can be produced efficiently in a high yield by a liquid-phase synthesis method, which includes subjecting a reaction mixture of a condensation reaction to an extraction operation and separating the morpholino oligonucleotide as a resultant product to the organic layer side.

8.

发明授权
Creatine phosphate analog prodrugs, compositions and methods of use thereof 有权

公开(公告)号：US11021501B2

公开(公告)日：2021-06-01

申请号：US15084732

申请日：2016-03-30

申请人： Farmington Pharma Development

发明人： William F. Brubaker

IPC分类号： C07F9/24 , C07F9/6533 , C07F9/655 , C07F9/6584 , C07B59/00 , C07F9/22

摘要： The invention describes membrane permeable creatine phosphate analog prodrugs, pharmaceutical compositions comprising membrane permeable creatine phosphate analog prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and genetic disorders affecting the creatine kinase system comprising administering creatine phosphate analog prodrugs or pharmaceutical compositions thereof. The invention also describes treating a genetic disease affecting the creatine kinase system, such as, for example, a creatine transporter disorder or a creatine synthesis disorder comprising administering creatine phosphate analog prodrugs or pharmaceutical compositions thereof.